Cargando…
Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions
BACKGROUND: HIV-1 infection generates numerous abnormalities in the B cell compartment which can be partly reversed by antiretroviral therapy. Our aim was to evaluate the effects that re-exposure to HIV antigens might have on the frequency and functionality of antibody secreting cells (ASC) in patie...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605223/ https://www.ncbi.nlm.nih.gov/pubmed/23433486 http://dx.doi.org/10.1186/1479-5876-11-48 |
_version_ | 1782263842085011456 |
---|---|
author | Llano, Anuska Carrillo, Jorge Mothe, Beatriz Ruiz, Lidia Marfil, Silvia García, Elisabet Yuste, Eloísa Sánchez, Víctor Clotet, Bonaventura Blanco, Julià Brander, Christian |
author_facet | Llano, Anuska Carrillo, Jorge Mothe, Beatriz Ruiz, Lidia Marfil, Silvia García, Elisabet Yuste, Eloísa Sánchez, Víctor Clotet, Bonaventura Blanco, Julià Brander, Christian |
author_sort | Llano, Anuska |
collection | PubMed |
description | BACKGROUND: HIV-1 infection generates numerous abnormalities in the B cell compartment which can be partly reversed by antiretroviral therapy. Our aim was to evaluate the effects that re-exposure to HIV antigens might have on the frequency and functionality of antibody secreting cells (ASC) in patients undergoing structured treatment interruptions (STI). As re-exposure to viral antigens may also boost the production of (neutralizing) antibodies, we also assessed the neutralizing activities during STI cycles. METHODS: Retrospective study of 10 patients undergoing 3 cycles of STI with 2 weeks on and 4 weeks off HAART. ASC frequencies were determined by flow cytometry in samples obtained at the beginning and the end of STI. Neutralization capacity, total IgG concentration and anti-gp120-IgG titres were evaluated. RESULTS: As expected, median viral loads were higher at the end of STI compared to on-HAART time points. The level of CD27 and CD38 expressing ACS followed the same pattern; with ASC being elevated up to 16 fold in some patients (median increase of 3.5% ± 4.13). Eight out of 10 patients maintained stable total IgG levels during the study. After purifying IgG fractions from plasma, HIV-neutralizing activity was observed in the two subjects with highest anti-gp120 titers. In one of these patients the neutralizing activity remained constant while the other showed elevated neutralizing Ab after first STI and once treatment was reinitiated after the 2(nd) STI. CONCLUSIONS: Our data suggest that STI and its associated transient increases in viral load drive the frequencies of ASC in an antigen-specific manner. In some subjects, this re-exposure to autologous virus boosts the presence of neutralizing antibodies, similar to what is seen after influenza vaccination. STI may not boost clinically beneficial nAb levels but offers opportunities to isolate nAb producing cells at considerably higher levels than in subjects with completely suppressed viral replication. |
format | Online Article Text |
id | pubmed-3605223 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-36052232013-03-22 Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions Llano, Anuska Carrillo, Jorge Mothe, Beatriz Ruiz, Lidia Marfil, Silvia García, Elisabet Yuste, Eloísa Sánchez, Víctor Clotet, Bonaventura Blanco, Julià Brander, Christian J Transl Med Research BACKGROUND: HIV-1 infection generates numerous abnormalities in the B cell compartment which can be partly reversed by antiretroviral therapy. Our aim was to evaluate the effects that re-exposure to HIV antigens might have on the frequency and functionality of antibody secreting cells (ASC) in patients undergoing structured treatment interruptions (STI). As re-exposure to viral antigens may also boost the production of (neutralizing) antibodies, we also assessed the neutralizing activities during STI cycles. METHODS: Retrospective study of 10 patients undergoing 3 cycles of STI with 2 weeks on and 4 weeks off HAART. ASC frequencies were determined by flow cytometry in samples obtained at the beginning and the end of STI. Neutralization capacity, total IgG concentration and anti-gp120-IgG titres were evaluated. RESULTS: As expected, median viral loads were higher at the end of STI compared to on-HAART time points. The level of CD27 and CD38 expressing ACS followed the same pattern; with ASC being elevated up to 16 fold in some patients (median increase of 3.5% ± 4.13). Eight out of 10 patients maintained stable total IgG levels during the study. After purifying IgG fractions from plasma, HIV-neutralizing activity was observed in the two subjects with highest anti-gp120 titers. In one of these patients the neutralizing activity remained constant while the other showed elevated neutralizing Ab after first STI and once treatment was reinitiated after the 2(nd) STI. CONCLUSIONS: Our data suggest that STI and its associated transient increases in viral load drive the frequencies of ASC in an antigen-specific manner. In some subjects, this re-exposure to autologous virus boosts the presence of neutralizing antibodies, similar to what is seen after influenza vaccination. STI may not boost clinically beneficial nAb levels but offers opportunities to isolate nAb producing cells at considerably higher levels than in subjects with completely suppressed viral replication. BioMed Central 2013-02-22 /pmc/articles/PMC3605223/ /pubmed/23433486 http://dx.doi.org/10.1186/1479-5876-11-48 Text en Copyright ©2013 LLano et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Research Llano, Anuska Carrillo, Jorge Mothe, Beatriz Ruiz, Lidia Marfil, Silvia García, Elisabet Yuste, Eloísa Sánchez, Víctor Clotet, Bonaventura Blanco, Julià Brander, Christian Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title_full | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title_fullStr | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title_full_unstemmed | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title_short | Expansion of antibody secreting cells and modulation of neutralizing antibody activity in HIV infected individuals undergoing structured treatment interruptions |
title_sort | expansion of antibody secreting cells and modulation of neutralizing antibody activity in hiv infected individuals undergoing structured treatment interruptions |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605223/ https://www.ncbi.nlm.nih.gov/pubmed/23433486 http://dx.doi.org/10.1186/1479-5876-11-48 |
work_keys_str_mv | AT llanoanuska expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT carrillojorge expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT mothebeatriz expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT ruizlidia expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT marfilsilvia expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT garciaelisabet expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT yusteeloisa expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT sanchezvictor expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT clotetbonaventura expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT blancojulia expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions AT branderchristian expansionofantibodysecretingcellsandmodulationofneutralizingantibodyactivityinhivinfectedindividualsundergoingstructuredtreatmentinterruptions |